EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Inborn Errors of Metabolism with Ataxia: Current and Future Treatment Options

Tatiana Bremova-Ertl iD, Jan Hofmann, Janine Stucki, Anja Vossenkaul, Matthias Gautschi iD

Cells · 19.09.2023 · 12 (18) · 2314

DOI: 10.3390/cells12182314 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 19.09.2023. Verfasst von Tatiana Bremova-Ertl und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Bern (Inselspital) and University of Bern, 3010 Bern, Switzerland. Hauptthemen laut MEDLINE: Metabolism, Inborn Errors, Ataxia, Cerebellar Ataxia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 251 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bern.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A number of hereditary ataxias are caused by inborn errors of metabolism (IEM), most of which are highly heterogeneous in their clinical presentation. Prompt diagnosis is important because disease-specific therapies may be available. In this review, we offer a comprehensive overview of metabolic ataxias summarized by disease, highlighting novel clinical trials and emerging therapies with a particular emphasis on first-in-human gene therapies. We present disease-specific treatments if they exist and review the current evidence for symptomatic treatments of these highly heterogeneous diseases (where cerebellar ataxia is part of their phenotype) that aim to improve the disease burden and enhance quality of life. In general, a multimodal and holistic approach to the treatment of cerebellar ataxia, irrespective of etiology, is necessary to offer the best medical care. Physical therapy and speech and occupational therapy are obligatory. Genetic counseling is essential for making informed decisions about family planning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolism, Inborn ErrorsAtaxiaCerebellar AtaxiaHumansGenetic Therapy

Stichwörter der Autor:innen

GM2-gangliosidosisNiemann-Pick type Cabetalipoproteinemiaacetyl-DL-leucineacetyl-L-leucinebiomarkerscerebellar ataxiacerebrotendinous xanthomatosisdisease-modifying treatmentdisorders of carbohydrate metabolismhereditary metabolic ataxiainborn error of metabolismlysosomal storage disordersmetabolic diseasesneurodegeneration

Autor:innen und Institutionen

  • Department of Neurology, University Hospital Bern (Inselspital) and University of Bern, 3010 Bern, Switzerland.
  • Center for Rare Diseases, University Hospital Bern (Inselspital) and University of Bern, 3010 Bern, Switzerland.
  • Division of Pediatric Endocrinology, Diabetes and Metabolism, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
  • Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.

ORCID-Profile: Tatiana Bremova-Ertl, Matthias Gautschi

Förderung

  • University of Bern

Zitieren

APA

Bremova-Ertl, T., Hofmann, J., Stucki, J., Vossenkaul, A., & Gautschi, M. (2023). Inborn Errors of Metabolism with Ataxia: Current and Future Treatment Options. Cells, 12(18), 2314. https://doi.org/10.3390/cells12182314

Vancouver

Bremova-Ertl T, Hofmann J, Stucki J, Vossenkaul A, Gautschi M. Inborn Errors of Metabolism with Ataxia: Current and Future Treatment Options. Cells. 2023;12(18):2314. doi:10.3390/cells12182314

BibTeX
@article{BremovaErtl2023,
  author = {Bremova-Ertl, Tatiana and Hofmann, Jan and Stucki, Janine and Vossenkaul, Anja and Gautschi, Matthias},
  title = {Inborn Errors of Metabolism with Ataxia: Current and Future Treatment Options},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {18},
  pages = {2314},
  doi = {10.3390/cells12182314}
}
Kostenlos starten →